Publication:
Statins & risk of Clostridium difficile infection: A meta-analysis

dc.contributor.authorKarn Wijarnpreechaen_US
dc.contributor.authorPanadeekarn Panjawatananen_US
dc.contributor.authorCharat Thongprayoonen_US
dc.contributor.authorPatompong Ungpraserten_US
dc.contributor.otherFaculty of Medicine, Siriraj Hospital, Mahidol Universityen_US
dc.contributor.otherMayo Clinicen_US
dc.contributor.otherChiang Mai Universityen_US
dc.contributor.otherBassett Medical Centeren_US
dc.date.accessioned2020-01-27T07:38:02Z
dc.date.available2020-01-27T07:38:02Z
dc.date.issued2019-10-01en_US
dc.description.abstract© 2019 Indian Journal of Medical Research. Background & objectives: Clostridium difficile infection is one of the most common healthcare-associated infections worldwide. Recent epidemiologic studies have suggested that statin users may have a lower risk of C. difficile infection, although the results are inconsistent. This meta-analysis was conducted with the aim of summarizing all available data to assess the risk of C. difficile infection among statin users versus non-users. Methods: A literature review was performed using the MEDLINE and EMBASE databases from inception to October 2017. Cohort, case-control and cross-sectional studies that compared the risk of C. difficile infection among statin users versus non-users were included. Pooled odds ratio (OR) and 95 per cent confidence interval (CI) were calculated using a random-effect, generic inverse variance method. Results: Six case-control studies and two cross-sectional studies met the eligibility criteria and were included in this meta-analysis. The risk of C. difficile infection among statin users was significantly lower than non-users with the pooled OR of 0.74 (95% CI, 0.61-0.89). The statistical heterogeneity of this study was high (I[2]=90%). Interpretation & conclusions: This meta-analysis demonstrated a decreased risk of C. difficile infection among statin users versus non-users. Further studies are required to clarify the role of statins for prevention of C. difficile infection in clinical practice.en_US
dc.identifier.citationIndian Journal of Medical Research. Vol.150, No.4 (2019), 359-364en_US
dc.identifier.doi10.4103/ijmr.IJMR_1973_17en_US
dc.identifier.issn09715916en_US
dc.identifier.other2-s2.0-85075942372en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/50065
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85075942372&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.titleStatins & risk of Clostridium difficile infection: A meta-analysisen_US
dc.typeReviewen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85075942372&origin=inwarden_US

Files

Collections